BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21191401)

  • 1. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.
    Ortonne N; Ram-Wolff C; Giustiniani J; Marie-Cardine A; Bagot M; Mecheri S; Bensussan A
    J Invest Dermatol; 2011 Apr; 131(4):916-24. PubMed ID: 21191401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD160: a unique activating NK cell receptor.
    Le Bouteiller P; Tabiasco J; Polgar B; Kozma N; Giustiniani J; Siewiera J; Berrebi A; Aguerre-Girr M; Bensussan A; Jabrane-Ferrat N
    Immunol Lett; 2011 Aug; 138(2):93-6. PubMed ID: 21324341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
    Giustiniani J; Marie-Cardine A; Bensussan A
    J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.
    Giustiniani J; Alaoui SS; Marie-Cardine A; Bernard J; Olive D; Bos C; Razafindratsita A; Petropoulou A; de Latour RP; Le Bouteiller P; Bagot M; Socié G; Bensussan A
    Curr Mol Med; 2012 Feb; 12(2):188-98. PubMed ID: 22172098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation.
    Abecassis S; Giustiniani J; Meyer N; Schiavon V; Ortonne N; Campillo JA; Bagot M; Bensussan A
    J Invest Dermatol; 2007 May; 127(5):1161-6. PubMed ID: 17218942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
    Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
    Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.
    Giustiniani J; Bensussan A; Marie-Cardine A
    J Immunol; 2009 Jan; 182(1):63-71. PubMed ID: 19109136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
    Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation.
    Maeda M; Carpenito C; Russell RC; Dasanjh J; Veinotte LL; Ohta H; Yamamura T; Tan R; Takei F
    J Immunol; 2005 Oct; 175(7):4426-32. PubMed ID: 16177084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
    Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
    Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD160 is essential for NK-mediated IFN-γ production.
    Tu TC; Brown NK; Kim TJ; Wroblewska J; Yang X; Guo X; Lee SH; Kumar V; Lee KM; Fu YX
    J Exp Med; 2015 Mar; 212(3):415-29. PubMed ID: 25711213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
    D'Addio F; Ueno T; Clarkson M; Zhu B; Vergani A; Freeman GJ; Sayegh MH; Ansari MJ; Fiorina P; Habicht A
    PLoS One; 2013; 8(4):e60391. PubMed ID: 23593209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
    Gauci ML; Giustiniani J; Lepelletier C; Garbar C; Thonnart N; Dumaz N; Foussat A; Lebbé C; Bensussan A; Marie-Cardine A
    Cancer Immunol Immunother; 2022 Nov; 71(11):2731-2742. PubMed ID: 35428910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells.
    Merino J; Ramírez N; Moreno C; Toledo E; Fernández M; Sánchez-Ibarrola A
    Clin Exp Immunol; 2007 Jul; 149(1):87-96. PubMed ID: 17425655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of murine CD160+ CD8+ T lymphocytes.
    Tsujimura K; Obata Y; Matsudaira Y; Nishida K; Akatsuka Y; Ito Y; Demachi-Okamura A; Kuzushima K; Takahashi T
    Immunol Lett; 2006 Jul; 106(1):48-56. PubMed ID: 16764942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.
    Nikolova M; Marie-Cardine A; Boumsell L; Bensussan A
    Int Immunol; 2002 May; 14(5):445-51. PubMed ID: 11978774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
    Scheffges C; Devy J; Giustiniani J; Francois S; Cartier L; Merrouche Y; Foussat A; Potteaux S; Bensussan A; Marie-Cardine A
    Breast Cancer Res; 2024 Feb; 26(1):28. PubMed ID: 38360636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.
    Chibueze CE; Yoshimitsu M; Arima N
    Biochem Biophys Res Commun; 2014 Oct; 453(3):379-84. PubMed ID: 25277889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engagement of the CD160 activating NK cell receptor leads to its association with CD2 in circulating human NK cells.
    Rabot M; Bensussan A; Le Bouteiller P
    Transpl Immunol; 2006 Dec; 17(1):36-8. PubMed ID: 17157212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.